Artelo Biosciences Inc (ARTL)
NASDAQ:ARTL
US Market
Holding ARTL?
Track your performance easily

Artelo Biosciences (ARTL) Income Statement

467 Followers

Artelo Biosciences Income Statement

Last quarter (Q2 2024), Artelo Biosciences's total revenue was $―, a decrease of ― from the same quarter last year. In Q2, Artelo Biosciences's net income was $-2.43M. See Artelo Biosciences’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Aug 21Aug 20Aug 19
Total Revenue
------
Cost of Revenue
------
Gross Profit
------
Operating Expense
$ 10.96M$ 9.93M$ 10.29M$ 7.44M$ 4.69M$ -3.21M
Operating Income
$ -10.96M$ -9.93M$ -10.29M$ -7.44M$ -4.69M$ -3.21M
Net Non Operating Interest Income Expense
--$ -3.00K$ 2.00K$ 1.00K$ 1.01M
Other Income Expense
$ 456.00K$ 641.00K$ 207.00K$ -2.00K$ -30.00K$ -31.26K
Pretax Income
$ -10.13M$ -9.29M$ -10.08M$ -7.44M$ -4.66M$ -2.17M
Tax Provision
$ 1.21M$ 1.21M$ 1.04M---
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -10.44M$ -9.29M$ -10.08M$ -7.44M$ -4.66M$ -2.17M
Basic EPS
$ -3.35$ -3.14-$ -6.00$ -18.90$ -15.00
Diluted EPS
$ -3.35$ -3.14-$ -6.00$ -18.90$ -21.90
Basic Average Shares
---$ 1.25B$ 247.18K$ 144.83K
Diluted Average Shares
---$ 1.25B$ 247.18K$ 144.83K
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 10.96M$ 9.93M$ 10.29M$ 7.44M$ 4.69M$ -3.21M
Net Income From Continuing And Discontinued Operation
$ -10.44M$ -9.29M$ -10.08M$ -7.44M$ -4.66M$ -2.17M
Normalized Income
$ -9.23M$ -7.34M----
Interest Expense
------
EBIT
$ -10.44M$ -9.29M$ -10.08M$ -7.44M$ -4.69M$ -2.17M
EBITDA
$ -10.44M$ -9.29M$ -10.08M$ -7.44M$ -4.69M$ -2.17M
Currency in USD

Artelo Biosciences Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis